UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor

Annals of oncology, 2018-10, Vol.29 (10), p.2145-2147

2018

Volltextzugriff (PDF)

Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

Annals of oncology, 2018-10, Vol.29, p.viii527-viii528

2018

Volltextzugriff (PDF)

P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study

Journal of thoracic oncology, 2024-10, Vol.19 (10), p.S407-S407

2024

Volltextzugriff (PDF)

4024 POSTER Customized Chemotherapy on the Basis of EGFR Mutation Status for Elderly Patients With Advanced Non-Small-Cell Lung Cancer

European journal of cancer (1990), 2011, Vol.47, p.S280-S280

2011

Volltextzugriff (PDF)

25P Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer

Annals of oncology, 2023-10, Vol.34, p.S194-S194

2023

Volltextzugriff (PDF)

MO32-1 Assessing the impact of comprehensive genome profiling in clinical practice: single-center observational study in Japan

Annals of oncology, 2024-10, Vol.35, p.S1343-S1344

2024

Volltextzugriff (PDF)

236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD

Annals of oncology, 2023-10, Vol.34, p.S275-S276

2023

Volltextzugriff (PDF)

1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD

Annals of oncology, 2023-10, Vol.34, p.S740-S741

2023

Volltextzugriff (PDF)

1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD

Annals of oncology, 2023-10, Vol.34, p.S737-S737

2023

Volltextzugriff (PDF)

EP1.14-08 Irreversible Severe Cardiotoxicities Except for QTc Interval Prolongation Associated with Osimertinib

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1034-S1035

2019

Volltextzugriff (PDF)

P1.04-77 Efficacy of Anti-PD-1/L1 Therapy for Advanced Non-Small Cell Lung Cancer with Preexisting Autoimmune Markers

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S472-S472

2019

Volltextzugriff (PDF)

P1.01-57 Association of Initial PD-L1 Expression with T790M-Acquired Resistance in Advanced EGFR-Mutant Lung Adenocarcinoma Patients

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S380-S380

2019

Volltextzugriff (PDF)

Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

Annals of oncology, 2019-10, Vol.30, p.v635-v636

2019

Volltextzugriff (PDF)

1544PThe safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1544P - The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

Annals of oncology, 2019-10, Vol.30, p.v635-v636

2019

Volltextzugriff (PDF)

1459PWhich of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)

Annals of oncology, 2019-11, Vol.30, p.ix175

2019

Volltextzugriff (PDF)

P1.04-62 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S465-S465

2019

Volltextzugriff (PDF)

Pulmonary cystic lesion in a trauma patient

Thorax, 2011-09, Vol.66 (9), p.830-830

2011

Volltextzugriff (PDF)

1327 - A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903

Annals of oncology, 2012-09, Vol.23, p.ix434-ix435

2012

Volltextzugriff (PDF)

A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903

Annals of oncology, 2012-09, Vol.23, p.ix434-ix435

2012

Volltextzugriff (PDF)

Drug-induced Interstitial Pneumonitis due to Low-dose Lenalidomide

Internal Medicine, 2012, Vol.51(9), pp.1081-1085

2012

Volltextzugriff (PDF)

Indole-3-carbinol suppresses tumor-induced angiogenesis by inhibiting tube formation and inducing apoptosis

Bioscience, biotechnology, and biochemistry, 2008-08, Vol.72 (8), p.2243-2246

2008

Volltextzugriff (PDF)

Propolis suppresses tumor angiogenesis by inducing apoptosis in tube-forming endothelial cells

Bioscience, biotechnology, and biochemistry, 2008-09, Vol.72 (9), p.2436-2440

2008

Volltextzugriff (PDF)

1 – 25 von 494

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(371)
Mit Volltextzugriff
(432)

Publikationsform

Sprache

Englisch
(479)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(350)
Life Sciences & Biomedicine
(160)
Physical Sciences
(155)
Humans
(109)
Technology
(104)
Optics
(95)
Biological And Medical Sciences
(89)
Male
(79)
Physics
(79)
Animals
(71)
Engineering
(68)
Engineering, Electrical & Electronic
(65)
Female
(62)
Exact Sciences And Technology
(61)
Medical Sciences
(59)
Middle Aged
(50)
Neurosciences & Neurology
(44)
Adult
(40)
Applied Sciences
(40)
Neurosciences
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor

Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study

4024 POSTER Customized Chemotherapy on the Basis of EGFR Mutation Status for Elderly Patients With Advanced Non-Small-Cell Lung Cancer

25P Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer

MO32-1 Assessing the impact of comprehensive genome profiling in clinical practice: single-center observational study in Japan

236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD

1282P Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD

1276P Genomic screening by multi-gene assay for perioperative targeted therapy in patients with early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD

EP1.14-08 Irreversible Severe Cardiotoxicities Except for QTc Interval Prolongation Associated with Osimertinib

P1.04-77 Efficacy of Anti-PD-1/L1 Therapy for Advanced Non-Small Cell Lung Cancer with Preexisting Autoimmune Markers

P1.01-57 Association of Initial PD-L1 Expression with T790M-Acquired Resistance in Advanced EGFR-Mutant Lung Adenocarcinoma Patients

Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients

The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

1544PThe safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

1544P - The safety assessment of crizotinib and alectinib from real-world data of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L)

1459PWhich of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?

A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)

P1.04-62 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC

Pulmonary cystic lesion in a trauma patient

1327 - A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903

A Phase II Trial of Cisplatin-Docetaxel-Bevacizmab Induction Chemotherapy Followed by Bevacizmab and Pemetrexed Maintenance Therapy in Patients with Nonsquamous Cell Lung Carcinoma: Okayama Lung Cancer Study Group Trial 0903

Drug-induced Interstitial Pneumonitis due to Low-dose Lenalidomide

Indole-3-carbinol suppresses tumor-induced angiogenesis by inhibiting tube formation and inducing apoptosis

Propolis suppresses tumor angiogenesis by inducing apoptosis in tube-forming endothelial cells

Suchergebnisse filtern